Compare Abbott Laboratories (ABT) vs Equinix Inc (EQIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Equinix Inc — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Equinix Inc trades at $1,019.99 (market cap $100.89B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | EQIX | |
|---|---|---|
Market Cap | $166.94B | $100.89B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $1.12K |
52-Week Low | $82.57 | $726.09 |
Enterprise Value | $193.69B | $121.17B |
Dividend Yield | 2.63% | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Equinix (EQIX) trades at $1,022.93, up 2.09% today, with a bearish technical signal despite recent AI partnership news. The stock shows strong revenue growth to $9.22B in 2025 and a net income margin of 15.07%, but faces high valuation multiples (P/E 69.08) and negative net cash flow. Analyst consensus is strongly bullish with a $1,190 price target, though recent earnings misses and elevated debt levels pose concerns.
Outlook remains mixed: AI infrastructure demand offers growth potential, but high leverage and valuation compression risks weigh on near-term upside. Investors should balance strong institutional support against execution risks and macroeconomic headwinds affecting capital-intensive expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
